Nestle set to increase stake in Aimmune Therapeutics to $273mn total

By Sean Galea-Pace
The Swiss-based food manufacturing company, Nestle, is set to significantly raise its stake in drug firm, Aimmune Therapeutics, as it begins to submit a...

The Swiss-based food manufacturing company, Nestle, is set to significantly raise its stake in drug firm, Aimmune Therapeutics, as it begins to submit a marketing application for its peanut allergy drug by the end of 2018, Reuters reports.

In a deal expected to be worth $98mn, the agreement will see Nestle’s stake rise to 19% from 14.5% as of the end of February, with its total investment in the company reaching $273mn.

It has also been announced that the companies have increased their two-year strategic pact to create therapies for food allergies by an additional two years.

See more:

Wedbush Securities analyst, Liana Moussatos, commented: “Some investors were worried that Nestle might sell their original equity investment in Aimmune. However, to us, this suggests Nestle views investment in Aimmune as long-term.”

According to Chief Executive Officer, Jayson Dallas, the launch of Aimmune’s oral drug, AR101, is said to be “well beyond” the expected approval and unveiling of the drug in the US.

It is anticipated the drug will be one of the first to be made available to patients in need for treatment options.

Share

Featured Articles

Future-proof your finance operations with automation

Join Dave Glennon from Eide Bailly & Colin King, CFO at USA Brands, for an on-demand webinar on how to future-proof your finance operations with automation

Giesecke+Devrient on new expectations for car manufacturers

Ralf Schedel leads market development in Giesecke+Devrient’s automotive business. Here, he discusses new expectations for car manufacturers

‘Factories of the Future’ & managing successful supply chain

China Performance Group’s Coral Li & Aurora Zhai discuss digital twins, ‘Factories of the Future’ & successful supply chains

Augury: Aged manufacturing ecosystem vs. tech advancements

Technology

4 ways Industry 4.0 makes factory maintenance easier

Technology

5 minutes with Peter Ross, founder and MD of CP Cases

Lean Manufacturing